Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

Health and Quality of Life Outcomes

Mark Kosinski¹  Ronald E DeGryse²  Lisa M Bloudek³  Sepideh F Varon²  Min Yang¹  Regina Rendas-Baum¹ 

[1] QualityMetric Incorporated, 24 Albion Road, Bldg 400, Lincoln 02865-4207, RI, USA;Allergan, Inc., 2525 Dupont Drive, Irvine 92612, CA, USA;Xcenda, LLC., 4114 Woodlands Pkwy, Palm Harbor 34685, FL, USA

关键词: PREEMPT;    Health-related quality of life;    Chronic migraine;    Validity;    Psychometrics;    Headache Impact Test (HIT-6);   

Others  :  1164558
DOI  :  10.1186/s12955-014-0117-0

 received in 2014-05-20, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

The Headache Impact Test (HIT)-6 was developed and has been validated in patients with various types of headache. The objective of this study was to report the psychometric properties of the HIT-6 among patients with chronic migraine.

Methods

Data came from two international, multicenter, randomized, double-blind, placebo-controlled clinical trials of chronic migraine patients (N = 1,384) undergoing prophylaxis therapy. Confirmatory factor analysis and differential item functioning (DIF) analysis were used to test the latent structure and cross-cultural comparability of the HIT-6. Reliability, construct validity, and responsiveness were assessed. Two sets of criterion groups were used: (1) 28-day headache frequency: <10, 10–14, and ≥15 days; (2) sample quartiles of the total cumulative hours of headache: <140, 140 to <280, 280 to <420, and ≥420 hours. Two sets of responsiveness categories were defined as reduction of <30%, 30% to <50%, or ≥50% in (1) number of headache days and (2) cumulative hours of headache.

Results

Measurement invariance tests supported the stability of the HIT-6 latent structure across studies. DIF analysis supported cross-cultural comparability. Good reliability was observed across studies (Cronbach’s α: 0.75–0.92; intraclass correlation coefficient: 0.76–0.80). HIT-6 scores correlated strongly (−0.86 to −0.59) with scores of the Migraine-Specific Quality-of-Life Questionnaire. Analysis of variance indicated that HIT-6 scores discriminated across both types of criterion groups (P<0.001), across studies and time points. HIT-6 change scores were significantly higher in magnitude in groups experiencing greater improvement (P<0.001).

Conclusion

All measurement properties were consistently verified across the two studies, supporting the validity of the HIT-6 among chronic migraine patients.

Trial registration

NCT00156910 webcite and NCT00168428 webcite on www.ClinicalTrials.gov webcite.

【 授权许可】

   
2014 Rendas-Baum et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
• [2]Rasmussen BK: Epidemiology of migraine. Biomed Pharmacother 1995, 49:452-455.
• [3]Lipton RB: Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009, 72:S3-S7.
• [4]Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB: Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008, 48:1157-1168.
• [5]Bigal ME, Lipton RB: Concepts and mechanisms of migraine chronification. Headache 2008, 48:7-15.
• [6]Bigal ME, Lipton RB: Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008, 71:848-855.
• [7]Holroyd KA: Assessment and psychological management of recurrent headache disorders. J Consult Clin Psychol 2002, 70:656-677.
• [8]Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ: Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008, 28:484-495.
• [9]Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB: Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000, 20:765-786.
• [10]Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S: A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003, 12:963-974.
• [11]Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K: Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache 2005, 45:638-643.
• [12]Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF: Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol 2006, 59:374-380.
• [13]De Hertogh W, Meiresone S, Wouters E, Cras P: A pilot study to assess the responsiveness of the headache impact test (HIT-6) [abstract]. Cephalalgia 2009, 29:79.
• [14]Usai S, Grazzi L, D’Amico D, Andrasik F, Bussone G: Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurol Sci 2008, 29(Suppl 1):S176-S178.
• [15]Yang M, Rendas-Baum R, Varon SF, Kosinski M: Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia 2011, 31:357-367.
• [16]Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30:793-803.
• [17]Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30:804-814.
• [18]Hu L, Bentler PM: Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Model 1999, 6:1-55.
• [19]Bayliss M, Batenhorst A: The HIT-6™ A User’s Guide. QualityMetric Incorporated, Lincoln, RI; 2002.
• [20]Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL: Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996, 42:36-42.
• [21]Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L: Development and validation of the migraine-specific quality of life questionnaire. Headache 1998, 38:295-302.
• [22]Millsap RE, Yun-Tein J: Assessing factorial invariance in ordered-categorical measures. Multivar Behav Res 2004, 39:479-515.
• [23][http://www.statmodel.com/examples/webnote.shtml#web10] webcite Asparouhov T, Muthen B: Robust Chi square difference testing with mean and variance adjusted test statistics.MPlus Web Notes 2006, .
• [24]Muthen LD, Muthen BO: MPlus User’s Guide. Muthen & Muthen, Los Angeles, CA; 2007.
• [25]Crane PK, Gibbons LE, Jolley L, van Belle G: Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect Difwithpar Med Care 2006, 44:S115-S123.
• [26]Millsap RE, Everson HT: Methodology review: statistical approaches for assessing measurement bias. Appl Psychol Meas 1993, 17:297-334.
• [27]Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 1993, 138:923-936.
• [28]Stokes ME, Davis CS, Koch GG: Categorical Analysis Using the SAS System. SAS Institute Inc., Cary, NC; 2000.
• [29]Fleiss JL: Design and Analysis of Clinical Experiments. John Wiley & Sons, New York; 1986.
• [30]Anastasi A, Urbina S: Psychological Testing. Prentice Hall, Upper Saddle River, NJ; 1997.
• [31]Nunnally JC, Bernstein IH: Psychometric Theory. McGraw-Hill, New York; 1994.
• [32]Clark LA, Watson D: Constructing validity: basic issues in objective scale development. Psychol Assess 1995, 7:309-319.
• [33]Kerlinger F: Foundations of Behavioral Research. Holt, Rinehart & Winston, New York; 1973.
• [34]Lipton RB, Bigal ME: Looking to the future: research designs for study of headache disease progression. Headache 2008, 48:58-66.
• [35]Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD: Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996, 28:171-177.
• [36]Scott NW, Fayers PM, Aaronson NK, de Bottomley A GA, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA: A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales. J Clin Epidemiol 2009, 62:288-295.
• [37]O’Connell A: Logistic Regression Models for Ordinal Response Variables. SAGE Publications, Thousand Oaks, CA; 2006.
• [38]Brant R: Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics 1990, 46:1171-1178.
• [39]Martin M, Blaisdell B, Kwong JW, Bjorner JB: The short-form headache impact test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol 2004, 57:1271-1278.